Richmond, VA, United States

Virginia Commonwealth University

www.vcu.edu
Richmond, VA, United States

Virginia Commonwealth University is a public research university located in Richmond, Virginia. VCU was founded in 1838 as the medical department of Hampden–Sydney College, becoming the Medical College of Virginia in 1854. In 1968, the Virginia General Assembly merged MCV with the Richmond Professional Institute, founded in 1917, to create Virginia Commonwealth University. Today, more than 31,000 students pursue 222 degree and certificate programs through VCU's 13 schools and one college. The VCU Health System supports the university's health care education, research and patient care mission.With a record $256 million in sponsored research funding in the fiscal year 2011, VCU is designated as a research university with very high research activity by the Carnegie Classification of Institutions of Higher Education. A broad array of university-approved centers and institutes of excellence, involving faculty from multiple disciplines in public policy, biotechnology and health care discoveries, supports the university's research mission. Twenty-eight graduate and first-professional programs are ranked by U.S. News and World Report as among the best in the country. VCU's athletic teams compete in Division I of the NCAA and are collectively known as the VCU Rams. They are members of the Atlantic 10 Conference. The VCU campus includes historic buildings such as the Ginter House, now used by the school's provost. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Virginia Commonwealth University | Date: 2017-08-16

Stage-specific Borrelia antigens for diagnosing, treating and/or preventing Lyme disease are provided. The antigens include chimeric Borrelia antigen constructs and mutant recombinant proteins comprising OspC and OspE epitopes, respectively. The antigens are used in multiprotein assays that differentiate early, middle and late stage infection, and/or in vaccine preparations.


Patent
Virginia Commonwealth University | Date: 2017-04-05

Methods and compositions for enhancing the ability of hypoxia-activated bioreductive agents to kill tumor cells within solid tumors are provided. Local regions of hypoxia are created within a tumor, or within a region containing a tumor, resulting in enhanced activation of hypoxia-activated bioreductive agents (e.g. tirapazamine) within the local region. The activated hypoxia-activated bioreductive agents kill tumor cells in the hypoxic region by catalyzing DNA stand breakage within the tumor cells. Because the activity is localized, side effects that typically occur as a result of systemic administration of bioreductive agents are reduced.


Patent
Virginia Commonwealth University | Date: 2016-08-25

The system includes various embodiments of components, including (1) a sensor array, (2) a processor, (3) a transmitter, (4) a receiver-stimulator, and (5) an implantable electrode array. The gustatory implant system generates tastant fingerprints by detecting tastants with an array of chemical sensors and then transmitting variable spatiotemporal stimulation patterns for an electrode array with electrode stimulating points positioned at different locations in the gustatory cortex (e.g., stimulating the chorda tympanic nerve). Different patterns of activity in the gustatory cortex are thereby generated which mimic the sense of taste in a subject. Once trained the system should be usable by a subject to detect or correctly identify or perceive one or more tastes. The system may also include an external electronic device for processing and displaying information to monitor ingestion of various substances in a subject.


Patent
Virginia Commonwealth University and The Regents Of The University Of Colorado | Date: 2016-08-31

In one example implementation, a method includes receiving, at a computing device, a request to grant a set of requested permissions to an application installed on the computing device, and sending, from the computing device, a permission query request to a recommendation server, where the permission query request includes an identifier for the application, and the set of requested permissions. The method may also include receiving, at the computing device, from the recommendation server, a set of permission recommendations, where the set of permission recommendations indicates whether the recommendation server recommends granting each requested permission from the set of requested permissions. The method may also include displaying the set of requested permissions and the set of permission recommendations, determining a set of granted permissions for the application, granted by a user of the computing device, from the set of requested permissions, and setting the permissions for the application on the computing device using the set of granted permissions.


Methods and compositions are provided for the prevention and/or treatment of symptoms associated with lipid accumulation disorders caused by attenuated leptin activity and by lipid storage disorders. The methods involve administering at least one oxygenated cholesterol sulfate (OCS) to a subject with the disorder. The disorder may be acquired or congenital (hereditary).


Patent
Virginia Commonwealth University | Date: 2016-03-24

A compound having the formula:


Patent
Virginia Commonwealth University | Date: 2016-11-25

Antigenic polypeptides comprising linear immunodominant epitopes of Borrelia outer surface protein A (OspA) or Borrelia outer surface protein C (OspC) are useful as vaccines against Lyme disease, and as diagnostics for detecting Borrelia infections. The OspA and OspC antigenic polypeptides typically comprise a plurality of peptides representing epitope containing regions from multiple distinct phyletic groups. The antigenic polypeptides may also include epitopes from both Borrelia OspA and Borrelia OspC.


Patent
The Penn State Research Foundation and Virginia Commonwealth University | Date: 2017-09-27

Provided are compositions and methods for use in polycystic ovary syndrome diagnosis (PCOS). The method involves a sample from a subject for a DENND1A Variant 2 mRNA or DENND1A Variant 2 protein to make or aid in a diagnosis of PCOS. Also provided are methods for selecting an individual as a candidate for therapy for polycystic ovary syndrome by testing a biological sample from an individual for DENND1A Variant 2 mRNA or DENND1A Variant 2 protein and designating the individual as a candidate for the PCOS based on determining DENND1A Variant 2 mRNA or DENND1A Variant 2 protein in the sample. Also provided are products for use in aiding diagnosis of PCOS which contain reagents for detecting DENND1A Variant 2 mRNA or DENND1A Variant 2 protein, and packaging containing printed material describing use and indications for the product.


Rodriguez-Menchaca A.A.,Virginia Commonwealth University
Proceedings of the National Academy of Sciences of the United States of America | Year: 2012

Voltage-gated K(+) (Kv) channels couple the movement of a voltage sensor to the channel gate(s) via a helical intracellular region, the S4-S5 linker. A number of studies link voltage sensitivity to interactions of S4 charges with membrane phospholipids in the outer leaflet of the bilayer. Although the phospholipid phosphatidylinositol-4,5-bisphosphate (PIP(2)) in the inner membrane leaflet has emerged as a universal activator of ion channels, no such role has been established for mammalian Kv channels. Here we show that PIP(2) depletion induced two kinetically distinct effects on Kv channels: an increase in voltage sensitivity and a concomitant decrease in current amplitude. These effects are reversible, exhibiting distinct molecular determinants and sensitivities to PIP(2). Gating current measurements revealed that PIP(2) constrains the movement of the sensor through interactions with the S4-S5 linker. Thus, PIP(2) controls both the movement of the voltage sensor and the stability of the open pore through interactions with the linker that connects them.


MacEyka M.,Virginia Commonwealth University | Spiegel S.,Virginia Commonwealth University
Nature | Year: 2014

Sphingolipids are ubiquitous building blocks of eukaryotic cell membranes. Progress in our understanding of sphingolipid metabolism, state-of-the-art sphingolipidomic approaches and animal models have generated a large body of evidence demonstrating that sphingolipid metabolites, particularly ceramide and sphingosine-1-phosphate, are signalling molecules that regulate a diverse range of cellular processes that are important in immunity, inflammation and inflammatory disorders. Recent insights into the molecular mechanisms of action of sphingolipid metabolites and new perspectives on their roles in regulating chronic inflammation have been reported. The knowledge gained in this emerging field will aid in the development of new therapeutic options for inflammatory disorders. © 2014 Macmillan Publishers Limited. All rights reserved.

Loading Virginia Commonwealth University collaborators
Loading Virginia Commonwealth University collaborators